Novartis India officially launched Pluvicto on June 16, 2026, marking the introduction of the first regulatory-approved radioligand therapy for advanced prostate cancer in the country. This precision medicine is specifically designed for patients with metastatic castration-resistant prostate cancer who test positive for the Prostate-Specific Membrane Antigen protein. The launch represents a significant milestone in India’s oncology sector, providing a new treatment avenue for patients who have exhausted conventional therapeutic options.
What is Pluvicto?
Pluvicto, known scientifically as lutetium (177Lu) vipivotide tetraxetan, is a targeted therapeutic agent used in nuclear medicine. It is a radioligand therapy (RLT) that combines a targeting compound, or ligand, with a therapeutic radioactive isotope called Lutetium-177. This therapy is imported to India from Novartis’ global manufacturing facilities located in Spain and Italy.
The drug is administered intravenously and acts like a “search and destroy” mission within the body. While traditional treatments like chemotherapy affect both healthy and diseased cells, Pluvicto is designed to be highly selective. It identifies specific markers on cancer cells, binds to them, and delivers a localized dose of radiation to destroy the tumor from within.
How Radioligand Therapy Works
Radioligand therapy is a form of precision medicine that utilizes the concept of theranostics, a combination of diagnostic and therapeutic techniques. The process begins with the ligand, which is a small molecule engineered to recognize and lock onto a specific protein found on the surface of cancer cells. In the case of Pluvicto, this ligand is Vipivotide Tetraxetan.
Once the ligand binds to the target protein, the entire complex is internalized, or pulled inside the cancer cell. The attached radioisotope, Lutetium-177, then undergoes decay and releases beta particles. These particles emit high energy radiation over a very short distance, typically between one to two millimeters. This short range ensures that the radiation is concentrated primarily on the cancer cell and its immediate vicinity, significantly reducing the exposure of healthy surrounding tissues to radiation. This targeted approach causes double strand DNA breaks within the cancer cell, eventually leading to its death.
Targeting PSMA-Positive Advanced Prostate Cancer
The effectiveness of Pluvicto relies on identifying the right targets. The therapy is indicated for patients with metastatic castration-resistant prostate cancer (mCRPC). This is a late stage form of prostate cancer where the disease has spread to other parts of the body and no longer responds to standard hormone treatments that lower testosterone levels.
A crucial requirement for this therapy is the presence of the Prostate-Specific Membrane Antigen (PSMA). PSMA is a protein that is overexpressed on the surface of approximately 80% to 90% of prostate cancer cells. Because its presence in healthy tissues is very limited, it serves as an ideal “address” for the drug. Before initiating treatment, patients undergo a specialized PSMA PET/CT scan to confirm that their tumors are PSMA-positive. This ensures that the therapy is only administered to those who are most likely to benefit, embodying the core principles of precision oncology.
Regulatory Framework and Infrastructure in India
The approval and rollout of a radiopharmaceutical like Pluvicto require a complex regulatory and logistical framework. In India, the primary regulatory body for drug approval is the Central Drugs Standard Control Organisation (CDSCO), which operates under the Ministry of Health and Family Welfare. The CDSCO is headquartered in New Delhi and is led by the Drugs Controller General of India (DCGI). Additionally, because the therapy involves radioactive materials, it must comply with the guidelines set by the Atomic Energy Regulatory Board (AERB), established in 1983 under the Atomic Energy Act, 1962.
Novartis India, led by Country President and Managing Director Amitabh Dube, is managing the distribution through a network of specialized nuclear medicine centers. The company is collaborating with more than 250 centers across the country to ensure that the necessary infrastructure for handling radioactive isotopes and providing multidisciplinary care is available. Since the radioactive component of the therapy has a relatively short half-life, the supply chain requires precise “just-in-time” logistics to ensure the medicine reaches the hospital while it is still therapeutically active.
Significance for Precision Oncology in India
Prostate cancer is one of the most common cancers among men in urban India, with approximately 50% of cases being diagnosed at an advanced or metastatic stage. The introduction of Pluvicto provides a critical therapeutic option for those who have developed resistance to standard androgen deprivation therapy and chemotherapy. Global clinical trials, such as the VISION study, have shown that this therapy significantly improves survival rates and reduces the risk of disease progression in patients with PSMA-positive mCRPC.
Beyond its immediate clinical impact, this launch strengthens India’s position as a hub for advanced medical treatments and precision oncology. By adopting globally recognized radioligand platforms, India is enhancing its healthcare infrastructure to meet the growing demand for personalized medicine. This development is expected to not only benefit domestic patients but also bolster India’s reputation in medical tourism, as it offers world class treatments at a fraction of the cost found in many Western nations.
Key Takeaways
- Pluvicto (lutetium (177Lu) vipivotide tetraxetan) is the first regulatory approved radioligand therapy in India for advanced prostate cancer.
- The therapy is specifically indicated for patients with PSMA-positive metastatic castration-resistant prostate cancer.
- Pluvicto uses the radioactive isotope Lutetium-177, which emits beta particles to deliver targeted radiation directly to cancer cells.
- The Central Drugs Standard Control Organisation (CDSCO), headquartered in New Delhi, provided the regulatory approval for the therapy.
- The Atomic Energy Regulatory Board (AERB), established in 1983, oversees the safety and handling of the radioactive components.
- Pre-treatment confirmation requires a PSMA PET/CT scan to verify the presence of the target protein on cancer cells.
